T1	Participants 2234 2336	CONCLUSIONS No significant difference in response rate or response duration was observed in this study
T2	Participants 0 257	Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
T3	Participants 495 625	OBJECTIVE To assess disease response and to compare the response rates of patients treated with PUVA alone or PUVA and bexarotene.
T4	Participants 626 820	METHODS EORTC 21011 (NCT 00056056) was a randomized phase III study comparing combined bexarotene (Targretin(Â®) ) and PUVA vs. PUVA alone in patients with stage IB and IIA mycosis fungoides (MF)
T5	Participants 1053 1156	Of the 93 randomized patients, 87 started treatment, 41 received PUVA and 46 received PUVA + bexarotene
